



Helsinki, 19 July 2018

Addressee:

Decision number: TPE-D-2114425135-59-01/F

Substance name: 1,1,3,3-TETRAMETHYLDISILOXANE

EC number: 221-906-4 CAS number: 3277-26-7

Registration number: Submission number:

Submission date: 16.04.2013

Registered tonnage band: 10-100T

DECISION ON A TESTING PROPOSAL

Based on Article 40 of Regulation (EC) No 1907/2006 (the 'REACH Regulation'), ECHA examined your testing proposal(s) and decided as follows.

Your testing proposal is accepted and you are requested to carry out:

- 1. Sub-chronic toxicity study (90-day), inhalation route (Annex IX, Section 8.6.2.; test method: OECD TG 413) in rats using the registered substance.
- 2. Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.; test method: EU B.31./OECD TG 414) in a first species (rat or rabbit), oral route using the registered substance.

You may adapt the testing requested above according to the specific rules outlined in Annexes VI to X and/or according to the general rules contained in Annex XI of the REACH Regulation. In order to ensure compliance with the respective information requirement, any such adaptation will need to have a scientific justification, referring and conforming to the appropriate rules in the respective Annex, and an adequate and reliable documentation.

You are required to submit the requested information in an updated registration dossier by **27 July 2020**. You shall also update the chemical safety report, where relevant.

The reasons of this decision are set out in Appendix 1. The procedural history is described in Appendix 2. Advice and further observations are provided in Appendix 3.



Appeal

This decision can be appealed to the Board of Appeal of ECHA within three months of its notification. An appeal, together with the grounds thereof, shall be submitted to ECHA in writing. An appeal has suspensive effect and is subject to a fee. Further details are described under http://echa.europa.eu/regulations/appeals.

Authorised¹ by Ofelia Bercaru, Head of Unit, Evaluation E3

 $^{^{1}}$ As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA's internal decision-approval process.



Appendix 1: Reasons

The decision of ECHA is based on the examination of the testing proposals submitted by you and any scientific information submitted by third parties.

1. Sub-chronic toxicity study (90-day) (Annex IX, Section 8.6.2.)

Pursuant to Article 40(3)(a) of the REACH Regulation, ECHA may require the Registrant to carry out the proposed test.

A sub-chronic toxicity study (90 day) is a standard information requirement as laid down in Annex IX, Section 8.6.2. of the REACH Regulation. The information on this endpoint is not available for the registered substance but needs to be present in the technical dossier to meet the information requirements. Consequently there is an information gap and it is necessary to provide information for this endpoint.

You have submitted a testing proposal for a sub-chronic toxicity study (90 day) in rats by the inhalation route according to OECD TG 413.

You proposed testing by the inhalation route. Since the registered substance is a liquid of high vapour pressure (18 kPa) and human exposure by the inhalation route is reported in the registration, ECHA considers that the inhalation route is the most appropriate route of administration. Hence, the test shall be performed by the inhalation route using the test method OECD TG 413.

You proposed testing in rats. According to the test method OECD TG 413 the rat is the preferred species. ECHA considers this species as being appropriate and testing should be performed with the rat.

In your comments to the draft decision you did not provide considerations to this specific endpoint.

Therefore, pursuant to Article 40(3)(a) of the REACH Regulation, you are requested to carry out the proposed study with the registered substance subject to the present decision: Subchronic toxicity study (90-day) in rats, inhalation route (test method: OECD TG 413).

2. Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.) in a first species

Pursuant to Article 40(3)(a) of the REACH Regulation, ECHA may require the Registrant to carry out the proposed test.

A pre-natal developmental toxicity study for a first species is a standard information requirement as laid down in Annex IX, Section 8.7.2. of the REACH Regulation. The information on this endpoint is not available for the registered substance but needs to be present in the technical dossier to meet the information requirements. Consequently there is an information gap and it is necessary to provide information for this endpoint.

You have submitted a testing proposal for a pre-natal developmental toxicity study in rats according to EU B.31./OECD TG 414.

CONFIDENTIAL 4 (6)



ECHA considers that the proposed study is appropriate to fulfil the information requirement of Annex IX, Section 8.7.2. of the REACH Regulation.

You proposed testing with the rat as a first species. According to the test method EU B.31./OECD TG 414, the rat is the preferred rodent species and the rabbit the preferred non-rodent species. On the basis of this default consideration, ECHA considers testing should be performed with the rat or rabbit as a first species.

You did not specify the route for testing. ECHA considers that the oral route is the most appropriate route of administration for substances except gases to focus on the detection of hazardous properties on reproduction as indicated in ECHA *Guidance on information requirements and chemical safety assessment* (version 6.0, July 2017) R.7a, chapter R.7.6.2.3.2. Since the substance to be tested is a liquid, ECHA concludes that testing should be performed by the oral route.

In your comments to the draft decision you did not provide considerations to this specific endpoint.

Therefore, pursuant to Article 40(3)(a) of the REACH Regulation, you are requested to carry out the proposed study with the registered substance subject to the present decision: Prenatal developmental toxicity study in a first species (rats or rabbits), oral route (test method: EU B.31./OECD TG 414).

Notes for your consideration

For the selection of the appropriate species you are advised to consult ECHA *Guidance on information requirements and chemical safety assessment* (version 6.0, July 2017), Chapter R.7a, section R.7.6.2.3.2.

ECHA notes that a revised version of OECD TG 414 was adopted this year by the OECD. This revised version contains enhancements of certain endocrine disrupting relevant parameters. You should test in accordance with the revised version of the guideline as published on the OECD website for adopted test guidelines (https://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-4-health-effects 20745788).

CONFIDENTIAL 5 (6)



Appendix 2: Procedural history

ECHA received your registration containing the testing proposal for examination pursuant to Article 40(1) on 16 April 2013.

ECHA notes that the tonnage band for several members of the joint submission is 100 to 1000 tonnes per year .

ECHA held a third party consultation for the testing proposals) from 29 April 2016 until 13 June 2016. ECHA did not receive information from third parties.

This decision does not take into account any updates after **5 September 2016**, 30 calendar days after the end of the commenting period.

ECHA notified you of the draft decision and invited you to provide comments. In your comments to the draft decision you did not provide specific considerations to the endpoint subject to the current decision.

You were notified that the draft decision does not take into account any updates after 05 September 2016, 30 calendar days after the end of the commenting period.

However, following your request and justification provided (including interlinked read-across testing strategy on several supposedly related registered substances) ECHA has exceptionally granted you additional time until 30 June 2017 for the update.

You did not update your registration dossier. ECHA took your comments into account, and did not amend the draft decision.

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA took the decision according to Article 51(3) of the REACH Regulation.



Appendix 3: Further information, observations and technical guidance

- 1. This decision does not imply that the information provided in your registration dossier is in compliance with the REACH requirements. The decision does not prevent ECHA from initiating a compliance check on the registration at a later stage.
- 2. Failure to comply with the request(s) in this decision, or to fulfil otherwise the information requirement(s) with a valid and documented adaptation, will result in a notification to the Enforcement Authorities of the Member States.
- 3. In relation to the information required by the present decision, the sample of the substance used for the new test(s) must be suitable for use by all the joint registrants. Hence, the sample should have a composition that is suitable to fulfil the information requirement for the range of substance compositions manufactured or imported by the joint registrants. It is the responsibility of all joint registrants who manufacture or import the same substance to agree on the appropriate composition of the test material and to document the necessary information on their substance composition. In addition, it is important to ensure that the particular sample of the substance tested in the new test(s) is appropriate to assess the properties of the registered substance, taking into account any variation in the composition of the technical grade of the substance as actually manufactured or imported by each registrant. If the registration of the substance by any registrant covers different grades, the sample used for the new test(s) must be suitable to assess these grades. Finally there must be adequate information on substance identity for the sample tested and the grade(s) registered to enable the relevance of the test(s) to be assessed.